Cencora shares target lifted to $284 on significant growth in the U.S market

On Wednesday, Citi updated its financial outlook on Cencora Inc (NYSE: COR), raising the stock’s price target from $280.00 to $284.00 and reaffirming a Buy rating. The adjustment follows Cencora’s third-quarter performance, which revealed significant growth in the U.S. market, surpassing analyst expectations.

Cencora’s third-quarter results showcased a 12% year-over-year increase in U.S. revenue and a 10% rise in adjusted operating income (AOI), which beat projections by 2%. These strong figures helped to counterbalance the softer international revenue and AOI growth of 0.1% and a decline of 4.1% respectively, which did not meet the analyst’s estimates by 4.5% and 6%.

In response to the quarterly outcomes, Cencora has adjusted its financial guidance. The company increased the lower end of its U.S. revenue/AOI forecast by one percentage point while trimming the upper end of its international guidance by the same margin. This revision implies an improvement of $16 million in enterprise AOI at the midpoint.

The earnings per share (EPS) forecast saw a more notable revision, with an increase of $0.15 at the midpoint. This enhancement was supported by a $20 million improvement in net interest expense due to higher cash balances, as Cencora has now raised its free cash flow (FCF) guidance to between $2.5 billion and $3 billion. Additionally, a reduction in the share count contributed to the EPS adjustment.

Citi’s updated stance on Cencora reflects optimism in the company’s ability to navigate market challenges and capitalize on its strengths, particularly in the U.S. market. The revised price target and maintained Buy rating indicate an expectation of continued positive performance for Cencora’s stock.

In other recent news, Cencora Inc. has experienced a series of positive financial developments. The company’s third-quarter earnings exceeded expectations, particularly in the United States with a 12% increase in revenue and a 10% rise in adjusted operating income. The strong U.S. performance has balanced a softer international performance, leading Cencora to revise its financial guidance. The company has raised its U.S. revenue and adjusted operating income forecast, and its earnings per share forecast has seen a significant increase.

In response to these developments, financial firms Citi and Baird have raised their price targets for Cencora shares, maintaining positive ratings. In addition, Cencora reported an 8% increase in revenue and a 9% rise in adjusted EPS during its Q2 2024 earnings call, and raised its adjusted operating income guidance for the full fiscal year.

Baird’s revised share price target for Cencora was based on a mix of valuation methodologies, including near-term and five-year forecasts. The firm also highlighted potential risks to Cencora’s business, such as customer concentration, potential impacts of opioid litigation, and possible changes in drug pricing policy. These are among the recent developments for Cencora, reflecting the company’s strong performance and positive outlook.

InvestingPro Insights

Following Citi’s positive outlook on Cencora Inc, InvestingPro data underscores several key financial metrics that may be of interest to investors. Cencora’s market capitalization stands at a robust $46.68 billion, with a Price/Earnings (P/E) ratio of 25.68, reflecting a premium valuation relative to its earnings. Despite a high P/E ratio, Cencora has demonstrated a commitment to shareholder returns, as evidenced by its impressive track record of raising its dividend for 19 consecutive years, a testament to its financial stability and investor-friendly approach.

InvestingPro Tips reveal strategic moves by management, such as aggressive share buybacks and maintaining dividend payments for 24 consecutive years. These actions suggest a management team that is confident in the company’s financial health and committed to delivering value to shareholders. Additionally, Cencora’s stock is known for low price volatility, providing a potentially more stable investment option in the Healthcare Providers & Services industry.

For investors seeking more in-depth analysis, InvestingPro offers additional tips on Cencora, including insights into the company’s revenue valuation multiples, liquidity position, and debt management. To explore these further, visit the dedicated page for Cencora at InvestingPro.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.